Last reviewed · How we verify
Glumetinib Tablets
At a glance
| Generic name | Glumetinib Tablets |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors (PHASE2)
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients (PHASE2, PHASE3)
- A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors (PHASE1)
- Study to Evaluate the Safety and Anti-tumor Activity of SCC244 (PHASE1)
- A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer (PHASE2)
- Single Dose Glumetinib in Healthy Chinese Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |